Do analysts rate PFSA or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, PFSA or VERO?

Profusa has higher earnings, but lower revenue than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profusa $100K 15.16 -$35.82M -$5.62 thousand N/A Venus Concept $58.88M 0.01 -$47M -$48.84 N/A

Is PFSA or VERO more profitable?

Profusa has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Profusa's return on equity of 0.00% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,731.09% Venus Concept -92.76% -1,904.25% -85.22%

Do analysts prefer BBLG or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend AEMD or VERO?

Aethlon Medical currently has a consensus price target of $1.50, indicating a potential downside of 1.96%. Given Aethlon Medical's stronger consensus rating and higher possible upside, research analysts plainly believe Aethlon Medical is more favorable than Venus Concept. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aethlon Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate DYNT or VERO?

Given Dynatronics' higher possible upside, research analysts plainly believe Dynatronics is more favorable than Venus Concept. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dynatronics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is DYNT or VERO more profitable?

Dynatronics has a net margin of -8.35% compared to Venus Concept's net margin of -92.76%. Dynatronics' return on equity of -41.81% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Dynatronics -8.35% -41.81% -9.56% Venus Concept -92.76% -1,904.25% -85.22%

Do analysts prefer VERO or BIOL?

Given BIOLASE's higher possible upside, analysts clearly believe BIOLASE is more favorable than Venus Concept. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is VERO or BIOL more profitable?

BIOLASE has a net margin of -41.65% compared to Venus Concept's net margin of -92.76%. BIOLASE's return on equity of -1,782.73% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Venus Concept -92.76% -1,904.25% -85.22% BIOLASE -41.65% -1,782.73% -55.31%

Venus Concept (VERO) Competitors

$0.31 0.00 (0.00%)

As of 09/11/2026

Compare

VERO vs. PFSA, BBLG, AEMD, DYNT, and BIOL

Should you buy Venus Concept stock or one of its competitors? Venus Concept's main competitors and comparable companies include Profusa (PFSA), Bone Biologics (BBLG), Aethlon Medical (AEMD), Dynatronics (DYNT), and BIOLASE (BIOL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Venus Concept compare to Profusa?

Profusa (NASDAQ:PFSA) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

9.8% of Profusa shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 15.0% of Profusa shares are owned by company insiders. Comparatively, 28.0% of Venus Concept shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profusa has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Profusa's return on equity of 0.00% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,731.09%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Profusa has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

Profusa has higher earnings, but lower revenue than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	15.16	-$35.82M	-$5.62 thousand	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

In the previous week, Profusa had 1 more articles in the media than Venus Concept. MarketBeat recorded 1 mentions for Profusa and 0 mentions for Venus Concept. Profusa's average media sentiment score of 1.87 beat Venus Concept's score of 0.00 indicating that Profusa is being referred to more favorably in the media.

Company	Overall Sentiment
Profusa	Very Positive
Venus Concept	Neutral

Summary

Profusa beats Venus Concept on 8 of the 13 factors compared between the two stocks.

How does Venus Concept compare to Bone Biologics?

Bone Biologics (NASDAQ:BBLG) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

In the previous week, Bone Biologics had 4 more articles in the media than Venus Concept. MarketBeat recorded 4 mentions for Bone Biologics and 0 mentions for Venus Concept. Bone Biologics' average media sentiment score of 0.96 beat Venus Concept's score of 0.00 indicating that Bone Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
Bone Biologics	Positive
Venus Concept	Neutral

Bone Biologics has higher earnings, but lower revenue than Venus Concept. Bone Biologics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bone Biologics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market.

Bone Biologics has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Bone Biologics' return on equity of -57.87% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-57.87%	-53.65%
Venus Concept	-92.76%	-1,904.25%	-85.22%

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 5.0% of Bone Biologics shares are owned by insiders. Comparatively, 28.0% of Venus Concept shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Bone Biologics beats Venus Concept on 8 of the 12 factors compared between the two stocks.

How does Venus Concept compare to Aethlon Medical?

Aethlon Medical (NASDAQ:AEMD) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Aethlon Medical has higher earnings, but lower revenue than Venus Concept. Aethlon Medical is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aethlon Medical	N/A	N/A	-$7.15M	-$34.97	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

Aethlon Medical has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Aethlon Medical's return on equity of -123.08% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aethlon Medical	N/A	-123.08%	-99.28%
Venus Concept	-92.76%	-1,904.25%	-85.22%

2.0% of Aethlon Medical shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 0.6% of Aethlon Medical shares are held by company insiders. Comparatively, 28.0% of Venus Concept shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aethlon Medical has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

Aethlon Medical currently has a consensus price target of $1.50, indicating a potential downside of 1.96%. Given Aethlon Medical's stronger consensus rating and higher possible upside, research analysts plainly believe Aethlon Medical is more favorable than Venus Concept.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aethlon Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Aethlon Medical had 2 more articles in the media than Venus Concept. MarketBeat recorded 2 mentions for Aethlon Medical and 0 mentions for Venus Concept. Aethlon Medical's average media sentiment score of 0.43 beat Venus Concept's score of 0.00 indicating that Aethlon Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Aethlon Medical	Neutral
Venus Concept	Neutral

Summary

Aethlon Medical beats Venus Concept on 9 of the 14 factors compared between the two stocks.

How does Venus Concept compare to Dynatronics?

Dynatronics (NASDAQ:DYNT) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

In the previous week, Dynatronics had 1 more articles in the media than Venus Concept. MarketBeat recorded 1 mentions for Dynatronics and 0 mentions for Venus Concept. Dynatronics' average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
Dynatronics	Neutral
Venus Concept	Neutral

4.2% of Dynatronics shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 2.9% of Dynatronics shares are owned by insiders. Comparatively, 28.0% of Venus Concept shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Dynatronics has a net margin of -8.35% compared to Venus Concept's net margin of -92.76%. Dynatronics' return on equity of -41.81% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dynatronics	-8.35%	-41.81%	-9.56%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Given Dynatronics' higher possible upside, research analysts plainly believe Dynatronics is more favorable than Venus Concept.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dynatronics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Dynatronics has higher earnings, but lower revenue than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

Dynatronics has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

Summary

Dynatronics beats Venus Concept on 8 of the 13 factors compared between the two stocks.

How does Venus Concept compare to BIOLASE?

Venus Concept (NASDAQ:VERO) and BIOLASE (NASDAQ:BIOL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

BIOLASE has lower revenue, but higher earnings than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A

Venus Concept has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

In the previous week, Venus Concept's average media sentiment score of 0.00 equaled BIOLASE'saverage media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
BIOLASE	Neutral

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 8.8% of BIOLASE shares are held by institutional investors. 28.0% of Venus Concept shares are held by insiders. Comparatively, 0.3% of BIOLASE shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Given BIOLASE's higher possible upside, analysts clearly believe BIOLASE is more favorable than Venus Concept.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

BIOLASE has a net margin of -41.65% compared to Venus Concept's net margin of -92.76%. BIOLASE's return on equity of -1,782.73% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
BIOLASE	-41.65%	-1,782.73%	-55.31%

Summary

BIOLASE beats Venus Concept on 8 of the 12 factors compared between the two stocks.

Get Venus Concept News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERO vs. The Competition

Export

Metric	Venus Concept	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$442K	$5.46B	$7.20B	$12.67B
Dividend Yield	N/A	1.80%	2.57%	11.71%
P/E Ratio	-0.01	25.19	275.02	25.43
Price / Sales	0.01	44.29	638.08	88.25
Price / Cash	N/A	33.03	28.42	34.96
Price / Book	0.07	6.01	10.32	6.23
Net Income	-$47M	$150.75M	$3.50B	$358.31M
7 Day Performance	N/A	-2.57%	-2.41%	-1.59%
1 Month Performance	N/A	-3.13%	0.22%	-2.89%
1 Year Performance	-86.67%	9.57%	24.17%	8.22%

Venus Concept Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERO Venus Concept	0.1093 of 5 stars	$0.31 flat	N/A	N/A	$442K	$58.88M	N/A	410
PFSA Profusa	1.0708 of 5 stars	$2.80 -2.8%	N/A	N/A	$1.71M	$100K	N/A	2
BBLG Bone Biologics	1.2571 of 5 stars	$0.59 +4.8%	N/A	-74.1%	$1.62M	N/A	N/A	2	Short Interest Decrease
AEMD Aethlon Medical	0.8359 of 5 stars	$1.74 -3.9%	$1.50 -13.8%	-96.0%	$1.25M	N/A	N/A	10	Short Interest Increase Gap Down
DYNT Dynatronics	N/A	N/A	N/A	N/A	$653K	$33.60M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERO) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Venus Concept (VERO) Competitors

VERO vs. PFSA, BBLG, AEMD, DYNT, and BIOL

How does Venus Concept compare to Profusa?

Summary

How does Venus Concept compare to Bone Biologics?

Summary

How does Venus Concept compare to Aethlon Medical?

Summary

How does Venus Concept compare to Dynatronics?

Summary

How does Venus Concept compare to BIOLASE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Venus Concept (VERO) Competitors

VERO vs. PFSA, BBLG, AEMD, DYNT, and BIOL

How does Venus Concept compare to Profusa?

Do insiders & institutionals hold more shares of PFSA or VERO?

Is PFSA or VERO more profitable?

Do analysts rate PFSA or VERO?

Which has more risk and volatility, PFSA or VERO?

Which has higher valuation and earnings, PFSA or VERO?

Does the media prefer PFSA or VERO?

Summary

How does Venus Concept compare to Bone Biologics?

Does the media prefer BBLG or VERO?

Which has preferable valuation & earnings, BBLG or VERO?

Do analysts prefer BBLG or VERO?

Which has more risk and volatility, BBLG or VERO?

Is BBLG or VERO more profitable?

Do institutionals & insiders have more ownership in BBLG or VERO?

Summary

How does Venus Concept compare to Aethlon Medical?

Which has preferable valuation & earnings, AEMD or VERO?

Is AEMD or VERO more profitable?

Do insiders and institutionals hold more shares of AEMD or VERO?

Which has more risk and volatility, AEMD or VERO?

Do analysts recommend AEMD or VERO?

Does the media prefer AEMD or VERO?

Summary

How does Venus Concept compare to Dynatronics?

Does the media refer more to DYNT or VERO?

Do insiders & institutionals hold more shares of DYNT or VERO?

Is DYNT or VERO more profitable?

Do analysts rate DYNT or VERO?

Which has preferable earnings & valuation, DYNT or VERO?

Which has more risk and volatility, DYNT or VERO?

Summary

How does Venus Concept compare to BIOLASE?

Which has better valuation & earnings, VERO or BIOL?

Which has more risk and volatility, VERO or BIOL?

Does the media prefer VERO or BIOL?

Do insiders and institutionals have more ownership in VERO or BIOL?

Do analysts prefer VERO or BIOL?

Is VERO or BIOL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools